Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (endometrial glandular cells) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 3 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 14994
Sealed predictions
- ADAMTS8 in dopamine neurons, braak-0.15 (p 0.699) → -0.60 (p 0.090)receipt 15001
Swarm cases
receipt 15001: ADAMTS8 in dopamine neurons, braak
- power
- full sample -0.35 (p 0.150, n 18), 95% CI -0.70 to +0.14. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.35 (p 0.150, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.46 (p 0.056, n 18). could be the mix.
- skeptic
- leave-one-out range -0.43 to -0.26, sign flips 0; without severely affected donors -0.35 (p 0.150, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.64 (p 0.0040, n 18) vs -0.35 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ADAMTS8 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ADAMTS8 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.78 p 0.0059 (needs p < 1.5e-4)
Receipts
loading the receipts